

Vinã-cius Campos de Molla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4118565/publications.pdf>

Version: 2024-02-01

20
papers

68
citations

1937457

4
h-index

1719901

7
g-index

23
all docs

23
docs citations

23
times ranked

48
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral shedding of herpesviruses and clinical outcomes in hematopoietic stem cell transplant patients. <i>Oral Diseases</i> , 2023, 29, 815-826.	1.5	0
2	HSCT FOR CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Journal of Bone Marrow Transplantation and Cellular Therapy</i> , 2021, 2, 72-80.	0.1	0
3	Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 692225.	2.2	19
4	Long-Term Follow-Up of Ruxolitinib in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 777.e1-777.e6.	0.6	4
5	Disruption of the oral microbiota is associated with a higher risk of relapse after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 17552.	1.6	16
6	VENETOCLAX FOR RELAPSED ACUTE MYELOID LEUCEMIA AS A BRIDGE FOR ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANTATION: A CASE REPORT. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 301-302.	0.1	1
7	Safety and Efficacy of Venetoclax Combined with Hypomethylating Agents or Low-Dose Cytarabine for Acute Myeloid Leukemia before and after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S300.	2.0	1
8	Increased Risk of for Cytomegalovirus Reactivation after Allogeneic HSCT in T-Cell Depleted Patients. <i>Blood</i> , 2020, 136, 36-37.	0.6	1
9	Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group. <i>Blood</i> , 2020, 136, 12-12.	0.6	0
10	Disruption of the Oral Microbiota Predicts Poor Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 44-45.	0.6	1
11	Long-Term Follow-up of Ruxolitinib in Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (GVHD). <i>Blood</i> , 2020, 136, 40-41.	0.6	0
12	"Low Dose Ganciclovir for Cytomegalovirus Reactivation after Allogeneic HSCT Is a Feasible Option with Same Efficacy and Less Toxicity Than Regular Dose". <i>Blood</i> , 2020, 136, 30-31.	0.6	0
13	Ikaros Expression in the Graft Is Associated with Chronic Graft Versus Host Disease. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
14	The impact of pretransplant malnutrition on allogeneic hematopoietic stem cell transplantation outcomes. <i>Clinical Nutrition ESPEN</i> , 2019, 33, 213-219.	0.5	14
15	Classical Monocyte Deficiency Calculated By the Mono-Index Can Predict Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Patients. <i>Blood</i> , 2019, 134, 5666-5666.	0.6	1
16	Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia. <i>Blood</i> , 2019, 134, 2503-2503.	0.6	1
17	Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy. <i>Blood</i> , 2019, 134, 1764-1764.	0.6	2
18	PIG-a Mutations in a Brazilian Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2019, 134, 944-944.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab. <i>Blood</i> , 2019, 134, 2222-2222.	0.6	3
20	NK CD56brightCD16neg reconstitution over Time (NK56-index) Significantly Impacts Long Term Outcome in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3295-3295.	0.6	0